Global brokerage firm Jefferies has upgraded Zydus Lifesciences to a ‘Buy’ rating, citing the strength of the company’s US pipeline as a major growth driver. Jefferies raised its target price to Rs 1,450 from Rs 1,210, indicating a 30% upside from the previous closing price of Rs 1,113.80.
Nilesh Shah on India’s next big growth plays and why market corrections are just short-lived blips
Nilesh Shah of Envision Capital explains that despite individual stocks experiencing significant declines, the overall stock market remains resilient with periodic corrections. He highlights strong